Browse Studies — Arctuva

Phase 3

A Phase 3, Open-label, Randomized, Standard of Care-controlled, Parallel Study Arm Study to Demonstrate Efficacy and Safety of ARINA-1 in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) Progression in Participants With a Bilateral Lung Transplant

The goal of this Phase 3 clinical trial is to compare ARINA-1 (a nebulized immunomodulatory agent) plus Standard of Care vs Standard of Care alone. The main qu…

Pre-Bronchiolitis Obliterans Syndrome

Estimated

~$10 – $8,750

Renovion, Inc.NCT05654922

Phase 2

A Randomized, Placebo-controlled Phase 2 Study to Demonstrate the Safety and Efficacy of the Addition of LAM-001 to Standard Immunosuppression Therapy for Chronic Lung Allograft Dysfunction (BOS).

The goal of this clinical trial is to learn about the safety and effectiveness of LAM-001 in patients who have developed bronchiolitis obliterans syndrome (BOS…

Bronchiolitis Obliterans SyndromeChronic Lung Allograft DysfunctionLung Transplantation

Estimated

~$10 – $7,500

Steven Hays, MDNCT06018766

Phase 2

An Open-Label, Phase 2 Study to Evaluate the Activity of Belumosudil in Subjects With New Onset and Incipient Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell Transplantation

The goal of this research study is to test the efficacy of a novel immunosuppressive agent, belumosudil, in allogeneic hematopoietic stem cell transplant (HSCT…

Bronchiolitis Obliterans SyndromeBronchiolitis ObliteransLung Diseases+1 more

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT05922761